Arcutis to Present at Upcoming Investor Conference
March 02, 2022 05:30 ET
|
Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., March 02, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in...
Arcutis Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
February 22, 2022 16:01 ET
|
Arcutis Biotherapeutics, Inc.
Received U.S. Food and Drug Administration (FDA) acceptance of the New Drug Application (NDA) for roflumilast cream for the treatment of plaque psoriasis in adults and adolescentsCompleted enrollment...
Arcutis Announces Data Comparing the Vehicle in Investigational Roflumilast Cream Against a Commercial Ceramide-Containing Moisturizing Cream
December 13, 2021 08:00 ET
|
Arcutis Biotherapeutics, Inc.
Data presented at Revolutionizing Atopic Dermatitis (RAD) ConferenceVehicle tested was comparable to the moisturizing cream based on primary endpoint of change in transepidermal water loss (TEWL) from...
Arcutis Announces Third Quarter 2021 Financial Results and Provides Business Update
November 04, 2021 16:02 ET
|
Arcutis Biotherapeutics, Inc.
Submitted New Drug Application (NDA) for roflumilast cream for the treatment of plaque psoriasis across the full spectrum of diseaseInitiated single pivotal Phase 3 trial of roflumilast foam in scalp...
Arcutis Submits Topical Roflumilast Cream New Drug Application to FDA for the Treatment of Adults and Adolescents with Plaque Psoriasis
October 04, 2021 08:00 ET
|
Arcutis Biotherapeutics, Inc.
Plaque psoriasis is a skin disease that affects approximately 8.6 million individuals in the U.S. and presents particular treatment challenges in certain anatomical regions.Roflumilast cream, a...
Arcutis Expands Patent Portfolio with Roflumilast Pharmacokinetics Patent
September 28, 2021 16:05 ET
|
Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in...
New Topical Roflumilast Data Presented at the European Academy of Dermatology and Venereology (EADV) Congress
September 27, 2021 08:05 ET
|
Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in...
Arcutis Announces Appointment of Keith Leonard to Board of Directors
September 02, 2021 16:10 ET
|
Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations to...
Bruce Binkowitz Joins Arcutis as Vice President of Biometrics
August 23, 2021 08:00 ET
|
Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations to...
Arcutis Announces Second Quarter 2021 Financial Results and Provides Business Update
August 05, 2021 16:05 ET
|
Arcutis Biotherapeutics, Inc.
Anticipates submission of a New Drug Application (NDA) for topical roflumilast cream as a potential treatment for plaque psoriasis late in the third quarter or early in the fourth quarter of...